Grand Journal of Urology
E-ISSN : 2757-7163

Can We Use the Silodosin as Second Line Treatment of Benign Prostate Hyperplasia?
Bekir Voyvoda1, Omur Memik1, Onur Karsli1, Murat Ustuner1, Levent Ozcan2
1Department of Urology, University of Health Sciences, Derince Training and Research Hospital, Kocaeli, Turkey
2Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey
DOI : 10.5222/GJU.2021.10820
Pages : 122-127
Objective: We aimed to investigate the efficacy of silodosin in patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) refractory to previous α-adrenergic receptor (AR) blocker therapy.

Materials and Methods: Patients who did not benefit from alpha-blocker therapy but avoided surgical treatment constitute the population of our study. Seventy-five patients were studied in each group; Group 1 was given 8 mg of silodosin, while Group 2 continued the previous alpha-blocker treatment.

Results: The initial mean international prostate symptom score (IPSS) was calculated as 20.81±0.97 in Group 1, in the third month there was a decrease of 17.12±1.25 (p<0.05). No significant change was observed in Group 2. In addition, a significant decrease was observed in IPSS subscores (storage and voiding symptoms) in Group 1 compared to baseline at the third month. There was an improvement in residual urine in the silodosin group and no improvement in the other group.

Conclusion: In patients with BPH who refuse surgical treatment and could not achieve adequate symptom relief with other α-blockers in routine practice, silodosin was found superior in terms of LUTS recovery. Silodosin is also an effective option in patients who cannot undergo surgical treatment due to comorbidities.

Keywords : silodosin, alpha blocker, benign prostate hyperplasia, BPH treatment
Viewed : 1924
Downloaded : 623
Creative Commons License
Can We Use the Silodosin as Second Line Treatment of Benign Prostate Hyperplasia? by Bekir Voyvoda is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.